On Thursday, Eli Lilly made an announcement revealing that its oral obesity drug, Orforglipron, yielded promising outcomes in a late-stage clinical trial. This medication assisted patients in retaining the majority of their weight loss even after they stopped using Tirzepatide Injection or Novo Nordisk's Semaglutide Injection. The company has already forwarded a marketing application for the drug's indication in treating obesity to the U.S. Food and Drug Administration (FDA). This application has been accorded priority review status, which is likely to expedite the review process. The trial findings indicated that patients who transitioned from Semaglutide to Orforglipron experienced an average weight regain of merely around 0.9 kg. In contrast, those who switched from Tirzepatide saw an average weight regain of approximately 5 kg. The oral drug's most frequently reported side effects were mild to moderate gastrointestinal reactions.